Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
CS-1 inhibitor
DRUG CLASS:
CS-1 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
elotuzumab (8)
RXDX-105 (5)
PVX-410 (0)
SLAMF7 FPBMC (0)
elotuzumab (8)
RXDX-105 (5)
PVX-410 (0)
SLAMF7 FPBMC (0)
›
Associations
(13)
News
Trials
Search handles
@CyclingDoctor
@DrRakeshPopat
@End_myeloma
@ManniMD1
@PLMcCarthyMD
@RahulBanerjeeMD
@bose_prithviraj
@dawood_findakly
Search handles
@CyclingDoctor
@DrRakeshPopat
@End_myeloma
@ManniMD1
@PLMcCarthyMD
@RahulBanerjeeMD
@bose_prithviraj
@dawood_findakly
Filter by
Latest
10ms
Hermann Einsele (@H_Einsele; @Uniklinikum_Wue) shares the findings of a Phase III study investigating elotuzumab plus KRd versus KRd in patients with newly diagnosed #MultipleMyeloma: 👉 https://t.co/0MrwIVUtMX 👈 @EHA_Hematology #MMsm #ImmunoOnc #EHA2023 (@VJHemOnc)
10 months ago
Clinical
|
Empliciti (elotuzumab)
11ms
Was good to present at #EHA23 the first results from our @MDAndersonNews IST on elotuzumab - clearly an active drug in MF - and an encore from #ASCO23 of the zilurgisertib (ACVR1/ALK2i) data showing anemia responses and hepcidin downregulation! #MPNSM (@bose_prithviraj)
11 months ago
ACVR1 (Activin A Receptor Type 1)
|
Empliciti (elotuzumab) • zilurgisertib (INCB00928)
11ms
Physician-scientist extraordinaire @BraunMDPhD with exciting new data using single cell RNA-seq to identify potential new targets for treating renal cell carcinoma! His work identified a SLAMF7 positive CD8 T cell population that strongly associates with adverse outcomes in… https://t.co/rtnIB1xsJ4 (@ZiadBakouny)
11 months ago
Clinical • Adverse events
|
CD8 (cluster of differentiation 8) • SLAMF7 (SLAM Family Member 7)
|
CD8 positive
11ms
#ASCO23 #mmsm Dr Knop: KRd vs elotuzumab and KRd in transplant-eligible patients with newly diagnosed #myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study - quads here to stay in upfront Rx!! @BldCancerDoc (@OncLive)
11 months ago
Clinical • P3 data
|
Empliciti (elotuzumab)
11ms
Didn't a cooperative group study elotuzumab in #MMsm before? Say, with a trial that started 12-11 years ago or something like that? (@RahulBanerjeeMD)
11 months ago
Empliciti (elotuzumab)
11ms
Elotuzumab continues to confuse us. After a string of failures- Elo improves post induction MRd negativity rates in a four vs three large randomized trial (n=579, Elo/KRd versus KRd, MRD neg 50% versus 35%). Whats going on here?! https://t.co/Fzf6EU6dDz… #mmsm #ASCO23 (@ManniMD1)
11 months ago
Clinical • Minimal residual disease
|
Empliciti (elotuzumab)
1year
FASCINATING 🇮🇹 @Cancers_MDPI study of ELISpot (T-cell responses) against BCMA,SLAMF7, etc. in pts with stable MGUS/SMM vs those who later develop #MMsm. More work to do, but maybe T-cell biology explains stable MGUS as much as myeloma cell biology does! https://t.co/876CGtIFO7 (@RahulBanerjeeMD)
1 year ago
Clinical
|
SLAMF7 (SLAM Family Member 7)
over1year
Wow, congratulations to this personal achievement! 👏 @H_Einsele is partner of our @CARAMBA_project, a #H2020 research project evaluating safety and efficacy of #SLAMF7 specific #CARTcells treating #MultipleMyeloma patients. (@ARTTIC_Inno)
over 1 year ago
Clinical • CAR T-Cell Therapy
|
SLAMF7 (SLAM Family Member 7)
almost2years
Well done #myeloma RT @EagleMyeloma: Why did Elotuzumab fail in #myeloma? 1. Soluble SLAMF7 interferes with the ADCC of Elo? 2. CD38 synapses with TC… https://t.co/MpnROVgcEj (@CyclingDoctor)
almost 2 years ago
SLAMF7 (SLAM Family Member 7)
|
Empliciti (elotuzumab)
almost2years
Why did Elotuzumab fail in #myeloma? 1. Soluble SLAMF7 interferes with the ADCC of Elo? 2. CD38 synapses with TCR, BCR, & CD16; so an Ab may interfere with TME? 3. Do Dara & Isa induce higher levels of complement-dependent cytotoxicity than Elo? #mmsm https://t.co/xx3YMSXzHf (@EagleMyeloma)
almost 2 years ago
SLAMF7 (SLAM Family Member 7)
|
Empliciti (elotuzumab)
almost2years
Manufacturing of UCARTCS1A - an allogeneic anti-SLAMF7/ CS1 CAR-T for myeloma. Importance in avoiding fratricide. #mmsm #COMy22 (@DrRakeshPopat)
almost 2 years ago
SLAMF7 (SLAM Family Member 7)
2years
MM: False +ve IgG-Kappa M-spike on Darat (Anti-CD38) -> Biotinylated rCD38 and streptavidin-coated magnetic beads. What about Elotuzumab (Anti-SLAMF7)? @Ramikomrokji @Dr_AmerZeidan @CyclingDoctor @drhusnain01 @MyelomaSLC @Myeloma_Doc @szusmani @SLentzsch @KRakszawski @myelomaMD (@dawood_findakly)
2 years ago
SLAMF7 (SLAM Family Member 7)
|
Empliciti (elotuzumab)
2years
4/ 📊 #BonumCE #MMSM SP is 63 yo/M presents w anemia & bone pain BMBX shows 70% clonal plasma cells and FISH reveals t(11;14) MRI shows multifocal bone lesions sBCMA is 227 ng/mL and SLAMF7 8.3 ng/mL by ELISA ☑️ Which is diagnostic of #multiplemyeloma in SP❓ (@End_myeloma)
2 years ago
SLAMF7 (SLAM Family Member 7)
2years
SLAMF7 engagement superactivates macrophages in acute and chronic inflammation. Not just Multiple Myeloma! https://t.co/noO5MIsMIO (@PLMcCarthyMD)
2 years ago
SLAMF7 (SLAM Family Member 7)
over2years
Trial in progress: anti-SLAMF7 elotuzumab in JAK2-mutated myelofibrosis w/ @bose_prithviraj of @MDAndersonNews Watch: 👉https://t.co/A7PG0wSgcn👈 #ASH21 @ASH_hematology #HemOnc #LymSM #LeuSM #MMsm (@VJHemOnc)
over 2 years ago
IO biomarker
|
JAK2 (Janus kinase 2)
|
JAK2 mutation
|
Empliciti (elotuzumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login